HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 4, 2019
- Accepted in final form July 1, 2019
- First Published August 12, 2019.
Author Disclosures
- Carles Gaig, MD, PhD,
- Guadalupe Ercilla, MD, PhD,
- Xavier Daura, PhD,
- Mario Ezquerra, PhD,
- Ruben Fernández-Santiago, PhD,
- Eduard Palou, MD, PhD,
- Lidia Sabater, PhD,
- Romana Höftberger, MD,
- Anna Heidbreder, MD, PhD,
- Birgit Högl, MD, PhD,
- Alex Iranzo, MD, PhD,
- Joan Santamaria, MD, PhD,
- Josep Dalmau, MD, PhD and
- Francesc Graus, MD, PhD
- Carles Gaig, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Guadalupe Ercilla, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Xavier Daura, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mario Ezquerra, PhD,
NONE
NONE
NONE
NONE
Patent Ref. Nr. UBTT304: ?Method for predicting L-DOPA induced dyskinesia onset and severity?. Inventors: M. J. Mart?, Dr. M. Ezquerra, Dr. R. Fern?ndez-Santiago. Invention: method for predicting the L-DOPA induced dyskinesia (LID) onset and severity in patients with Parkinson?s disease (PD) treated with this compound. Current stage of development: Priority patent application filed.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
MicroRNAs as biomarkers of the prodromal stage of Parkinson disease. Funding entity: The Michael J Fox Foundation for Parkinson?s Disease Research (MJFF). Amount: 210.791$. From: 2016 To: 2019 Co-Principal investigator: Mario Ezquerra (co-PI). MicroRNAs como biomarcadores de conversi?n de trastorno conductual de sue?o REM a enfermedad de Parkinson Funding entity: Fundacion Tatiana Guzman El Bueno. Amount: 77.000 euros. From: 2017 To: 2019. Principal investigator: Mario Ezquerra.
NONE
NONE
NONE
NONE
NONE
NONE
- Ruben Fernández-Santiago, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I, R.F.-S., was supported by a J?venes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigaci?n (AEI) (AEI/FEDER/UE) (grant # SAF2015-73508-JIN) (2016-2019).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eduard Palou, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Spanish government/Carlos III Health Institute, PI17/00078, Co-principal investigator, 2018-2020
NONE
(1) Foundation of the Academy of Medical and Health Sciences from Catalonia
NONE
NONE
NONE
NONE
NONE
NONE
- Lidia Sabater, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romana Höftberger, MD,
NONE
NONE
speaker honoraria from Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Heidbreder, MD, PhD,
NONE
NONE
speaker honoraria for UCB, Bioprojet, Servier, Medice
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Birgit Högl, MD, PhD,
1. Axovant2. Benevolent Bio3. Roche4. Takeda
NONE
speaker honorarium or travel support: (1) Habel Medizintechnik, Vienna, Austria(2) Novartis(3) AoP Orphan(4) Inspire
(1) J Clin Sleep Med;(2) Sleep Medicine;(3) Somnologieall without compensation
NONE
Disorders of Sleep and Circadian Rhythms in Parkinson?s disease. Springer, 2015REM Sleep Behavior Disorder. Srpinger, 2018
NONE
Mundipharma, UCB, Axovant, Benevolent Bio
NONE
Travel Support Habel Medizintechnik and Vivisol Austria
NONE
UCB
FWF Austrian Science Funds I2120 B27, PI, 2015-2018FWF Austrian Science Funds, KLI633
NONE
Government of Tyrol, no number, PI, 2012-2016
NONE
NONE
NONE
NONE
NONE
NONE
- Alex Iranzo, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Joan Santamaria, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grant from Fundaci? La Marat? TV3, Catalonia, Spain; 2015 to now
NONE
NONE
NONE
NONE
NONE
NONE
- Josep Dalmau, MD, PhD and
NONE
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
NONE
NONE
Advance Medical
NONE
NONE
NONE
NONE
-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -ERA-NET Neuron
NONE
NONE
NONE
NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun
Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests
NONE
NONE
NONE
- Francesc Graus, MD, PhD
NONE
NONE
NONE
member of the editorial Board of Lancet neurology since 2002
use of IgLON5 as a diagnostic test.
Dr. Graus receives royalties from licensing fees to Euroimmun for the use of IgLON5 as a diagnostic test.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Service of Neurology (C.G., A.I., J.S.), Hospital Clinic, Barcelona, Spain; Multidisciplinary Sleep Disorders Unit (C.G., A.I., J.S.), Hospital Clinic, Barcelona, Spain; Department of Immunology (G.E., E.P.), Hospital Clínic, Barcelona, Spain; Institute of Biotechnology and Biomedicine (X.D.), Universitat Autònoma de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA) (X.D., J.D.), Barcelona, Spain; Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E., R.F.-S.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Neuroimmunology Program (L.S., J.D., F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Institute of Neurology (R.H.), Medical University of Vienna, Austria; Institute for Sleep Medicine and Neuromuscular Disorders (A.H.), University Hospital Muenster, Muenster, Germany; Department of Neurology (B.H.), Medical University of Innsbruck, Innsbruck, Austria; and Department of Neurology (J.D.), University of Pennsylvania, Philadelphia, PA.
- Correspondence
Dr. Gaig cgaig{at}clinic.ub.es
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Clinical manifestations of the anti-IgLON5 diseaseCarles Gaig, Francesc Graus, Yarko Compta et al.Neurology, April 05, 2017 -
Article
In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoformsDavid T. Jones, David S. Knopman, Jonathan Graff-Radford et al.Neurology, February 09, 2018 -
Articles
HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndromeJ. J. Ma, M. Nishimura, H. Mines et al.Neurology, August 01, 1998 -
Article
Anti-IGLON5 diseaseA new case without neuropathologic evidence of brainstem tauopathyMaria Elena Erro, Lidia Sabater, Laura Martínez et al.Neurology: Neuroimmunology & Neuroinflammation, December 11, 2019